Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

A Treatment Option in Myelofibrosis

April 7th 2020

This OncLive webinar will uncover the latest treatments in myelofibrosis by Bart Scott, MD. Join us on Tuesday, April 28, 2020 or Thursday, April 30, 2020 at 5 PM or 8 PM EDT.

Dr. Cortes on the Safety Profile of Ruxolitinib in MPNs

April 7th 2020

Jorge E. Cortes, MD, discusses the safety profile of ruxolitinib in patients with myeloproliferative neoplasms.

MDS Armamentarium Expands With Luspatercept Approval, Novel Compounds

April 7th 2020

David P. Steensma, MD, discusses some new data in myelodysplastic syndromes and ongoing research in the space.

Dr. Jain on Treatment Options for Patients With Myelofibrosis Who Progress After Transplant

April 3rd 2020

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Dr. Garcia on Efficacy of Navitoclax in Ruxolitinib-Resistant Myelofibrosis

March 28th 2020

Jacqueline S. Garcia, MD, discusses results from a phase II trial examining the addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib.

Dr. Nagalla on Need for Timely Assays for DOACs in MPNs

March 27th 2020

Srikanth Nagalla, MD, discusses research efforts dedicated to the development of timely assays for direct oral anticoagulants in myeloproliferative neoplasms.

Dr. Nagalla on Aspirin Use During DOAC Treatment for MPNs

March 26th 2020

Srikanth Nagalla, MD, discusses aspirin recommendations for patients with myeloproliferative neoplasms who are receiving direct oral anticoagulants.

Dr. Mesa on Investigative Therapies in Myelofibrosis

March 26th 2020

Ruben Mesa, MD, discusses therapiesunder investigation in myelofibrosis.

Dr. Kremyanskaya on MANIFEST Trial With CPI-0610 in Myelofibrosis

March 26th 2020

Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.

Dr. Saint Fleur-Lominy on the Use of Ruxolitinib Versus Fedratinib in MPNs

March 25th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.

Mesa Discusses Next Steps in Myelofibrosis

March 25th 2020

Ruben Mesa, MD, discusses the latest advancements in the treatment paradigm for patients with myelofibrosis.

Dr. Cortes on the Utility of Ruxolitinib in MPNs

March 23rd 2020

Jorge E. Cortes, MD, discusses the utility of ruxolitinib in myeloproliferative neoplasms.

Dr. Garcia on Unmet Need in Myelofibrosis

March 23rd 2020

Jacqueline S. Garcia, MD, discusses unmet needs for patients with myelofibrosis who progress on JAK inhibitors.

Dr. Jain on the Role of Allogeneic Transplant in Myelofibrosis

March 23rd 2020

Tania Jain, MBBS, discusses the role of allogeneic stem cell transplant in myelofibrosis.

Dr. Saint Fleur-Lominy on the Role of Transplant in MPNs

March 20th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the role of transplant in myeloproliferative neoplasms.

Dr. Gerds on Design and Safety Analysis of a Trial With Luspatercept in Myelofibrosis

March 19th 2020

Aaron Gerds, MD, assistant professor of medicine in the Hematology and Medical Oncology Department at the Cleveland Clinic Taussig Cancer Institute, discusses the design and safety analysis of a phase II trial of luspatercept in patients with myelofibrosis-associated anemia.

Dr. Saint Fleur-Lominy on Emerging Agents in MPNs

March 19th 2020

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health

Ruxolitinib Combo Shows Potential in Post-MPN AML, But Unmet Need Remains

March 18th 2020

Prithviraj Bose, MD, discusses the high unmet need in post-myeloproliferative neoplasms acute myeloid leukemia and the impact of findings from the phase I/II trial on current and future treatment strategies in the space.

Case Series Shows Feasibility of Haploidentical Transplant in High-Risk Myelofibrosis

March 17th 2020

Haploidentical allogeneic stem cell transplant is a viable treatment option for patients with myelofibrosis who have a higher risk for posttransplant complications and mortality.

Dr. Mesa on the Utility of Fedratinib for Patients With Myelofibrosis Who Progress on Ruxolitinib

March 16th 2020

Ruben Mesa, MD, discusses the utility of fedratinib for patients with myelofibrosis who progress on first-line ruxolitinib.